JP2025508328A5 - - Google Patents

Info

Publication number
JP2025508328A5
JP2025508328A5 JP2024544403A JP2024544403A JP2025508328A5 JP 2025508328 A5 JP2025508328 A5 JP 2025508328A5 JP 2024544403 A JP2024544403 A JP 2024544403A JP 2024544403 A JP2024544403 A JP 2024544403A JP 2025508328 A5 JP2025508328 A5 JP 2025508328A5
Authority
JP
Japan
Prior art keywords
conjugate according
group
e3lb
conjugate
covalently bonded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544403A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/061218 external-priority patent/WO2023147329A1/en
Publication of JP2025508328A publication Critical patent/JP2025508328A/ja
Publication of JP2025508328A5 publication Critical patent/JP2025508328A5/ja
Pending legal-status Critical Current

Links

JP2024544403A 2022-01-26 2023-01-25 抗体にコンジュゲートした化学的分解誘導物質とその方法 Pending JP2025508328A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303446P 2022-01-26 2022-01-26
US63/303,446 2022-01-26
PCT/US2023/061218 WO2023147329A1 (en) 2022-01-26 2023-01-25 Antibody-conjugated chemical inducers of degradation and methods thereof

Publications (2)

Publication Number Publication Date
JP2025508328A JP2025508328A (ja) 2025-03-26
JP2025508328A5 true JP2025508328A5 (cg-RX-API-DMAC10.html) 2026-02-02

Family

ID=85283790

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544403A Pending JP2025508328A (ja) 2022-01-26 2023-01-25 抗体にコンジュゲートした化学的分解誘導物質とその方法

Country Status (7)

Country Link
US (1) US20250073345A1 (cg-RX-API-DMAC10.html)
EP (1) EP4469089A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025508328A (cg-RX-API-DMAC10.html)
CN (1) CN118647407A (cg-RX-API-DMAC10.html)
AR (1) AR128331A1 (cg-RX-API-DMAC10.html)
TW (1) TW202337500A (cg-RX-API-DMAC10.html)
WO (1) WO2023147329A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US20020187472A1 (en) 2001-03-09 2002-12-12 Preeti Lal Steap-related protein
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001072962A2 (en) 2000-03-24 2001-10-04 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU2001253140A1 (en) 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1445318A2 (en) 2000-08-24 2004-08-11 Genetech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CA2446788A1 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
MXPA03011979A (es) 2001-06-18 2005-04-08 Eos Biotechnology Inc Metodos de diagnostico de cancer de ovario composiciones y metodos para rastrear moduladores de cancer de ovario.
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP1476120B1 (en) 2002-02-21 2010-09-29 Duke University Treatment methods using anti-cd22 antibodies
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
MXPA04009728A (es) 2002-04-05 2005-06-08 Agenysys Inc Acido nucleico y proteina correspondiente titulada 98p4b6 en el tratamiento y deteccion del cancer.
WO2003104270A2 (en) 2002-06-06 2003-12-18 Ingenium Pharmaceuticals Ag Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
KR20050048615A (ko) 2002-08-19 2005-05-24 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
JP2006501849A (ja) 2002-10-04 2006-01-19 ヴァン アンデル リサーチ インスティチュート 腎腫瘍の分子サブ分類および新規診断マーカーの発見
EP1583820A4 (en) 2003-01-14 2007-07-18 Bristol Myers Squibb Co ASSOCIATED POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB WAY
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
WO2013017705A1 (es) 2011-08-03 2013-02-07 Salvador Moreno Rufino Baltasar Sistema de panel para construccion con retroiluminacion a base de diodos electroluminosos
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
PE20150025A1 (es) 2012-05-21 2015-02-09 Genentech Inc Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
KR20210132742A (ko) 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
BR112016014126B1 (pt) 2013-12-16 2023-02-14 Medimmune Limited Composto não-peptídico, conjugados de anticorpo-fármaco do mesmo, uso dos ditos conjugados para o tratamento de câncer e composição farmacêutica que compreende os mesmos
EP3167887B1 (en) 2014-07-07 2021-03-24 Chen, Kuenfeng Aryl amine substituted quinoxaline used as anticancer drugs
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック, インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
JP7502425B2 (ja) * 2019-10-01 2024-06-18 アルヴィナス・オペレーションズ・インコーポレイテッド Brm標的化化合物および関連使用方法
IL299860A (en) * 2020-07-21 2023-03-01 Genentech Inc Antibody-conjugated chemical factors for the discharge of BRM and their methods

Similar Documents

Publication Publication Date Title
JP2022095908A5 (cg-RX-API-DMAC10.html)
RU2004110055A (ru) Новые ингибиторы дипептидил пептидазы iv в качестве антидиабетических агентов
JP2021063088A5 (cg-RX-API-DMAC10.html)
JP2020536847A5 (cg-RX-API-DMAC10.html)
CN1429118A (zh) 芳香酶抑制剂和单克隆抗her2抗体作为抗肿瘤剂
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2020508985A5 (cg-RX-API-DMAC10.html)
JP2020516621A5 (cg-RX-API-DMAC10.html)
JP2021505540A5 (cg-RX-API-DMAC10.html)
RU2010116274A (ru) Аналоги азацитидина и их применение
JP2002543112A (ja) アントラサイクリン誘導体を含有する配合製剤
JP2021515017A5 (cg-RX-API-DMAC10.html)
JP2003522198A5 (cg-RX-API-DMAC10.html)
JP2023505434A5 (cg-RX-API-DMAC10.html)
JP2007520452A5 (cg-RX-API-DMAC10.html)
JP2022550174A5 (cg-RX-API-DMAC10.html)
JP2006503805A5 (cg-RX-API-DMAC10.html)
JP2025501978A5 (cg-RX-API-DMAC10.html)
CN109922834B (zh) 用于治疗癌症的卟啉化合物和组合物
JP2022537019A5 (cg-RX-API-DMAC10.html)
JP2025506357A5 (cg-RX-API-DMAC10.html)
CA2483826A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
JP2006517195A5 (cg-RX-API-DMAC10.html)
JP2022507265A5 (cg-RX-API-DMAC10.html)
JP2005505571A5 (cg-RX-API-DMAC10.html)